Drugs to minimize perioperative blood loss in cardiac surgery: Meta- analyses using perioperative blood transfusion as the outcome

Anesthesia and Analgesia

Volumn 85, Issue 6, 1997, Pages 1258-1267

  Laupacis, Andreas ^a   Fergusson, Dean ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; DESMOPRESSIN; TRANEXAMIC ACID;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL RECORD; META ANALYSIS; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME;

6-AMINOCAPROIC ACID; APROTININ; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; DEAMINO ARGININE VASOPRESSIN; HEMOSTATICS; HUMANS; PREMEDICATION; RANDOMIZED CONTROLLED TRIALS; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 0031415922     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199712000-00014     Document Type: Article

References (86)

1. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8.
2. Scott WJ, Kessler R, Wernly JA. Blood conservation in cardiac surgery. Ann Thorac Surg 1990;50:843-51.
3. Hashemi S, Palmer DS, Aye MT, et al. Molecular mechanisms of cellular responses to DDAVP. In: Mariani G, ed. Desmopressin in bleeding disorders. New York: Plenum, 1992:43-56.
4. Rubens F, Wells P. Tranexamic acid use during coronary artery bypass grafting. Ann Thorac Surg 1996;61:774-5.
5. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1995;58:1580-8.
6. Cattaneo M, Harris AS, Stroberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery: a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost 1995;74:1064-70.
7. Chalmers TC, Celano P, Sacks HS, Smith H. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983;309: 1358-61.
8. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effect in controlled trials. JAMA 1995;273:408-12.
9. Lemmer JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1659-68.
10. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Contr Clin Trials 1996;17:1-12.
11. Meta-Analyst.977.Lau J, Chalmers TC. 1990.
12. RevMan (1.04b): The Cochrane Review Manager. 1994.
13. Havel M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994;107:807-10.
14. Kalangos A, Tayyareci G, Pretre R, et al. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994;8:651-6.
15. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency - a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-51.
16. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147-52.
17. Rodrigus IE, Vermeyen KM, De Hert SG, et al. Efficacy and safety of aprotinin in aortocoronary bypass and valve replacement operations: a placebo-controlled randomized double-blind study. Perfusion 1996;11:313-8.
18. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
19. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97:364-72.
20. Fraedrich G, Weber C, Bernard C, et al. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin: preliminary results. Thorac Cardiovasc Surg 1989;37:89-91.
21. Locatelli A, Bertollo D, Bianchi T, et al. Aprotinin in cardiosurgery: a randomized prospective study with different protocols for use. Miner Anestesiol 1990;56:973-5.
22. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-26.
23. Boldt J, Zickmann B, Czeke A, et al. Blood conservation techniques and platelet function in cardiac surgery. Anesthesiology 1991;75:426-32.
24. Gherli T, Porcu A, Padua G, et al. Reducing bleeding during extracorporeal circulation interventions by high doses of aprotinin. Min Cardioangiol 1992;40:121-6.
25. Deleuze P, Loisance DY, Feliz A, et al. Reduction of pre- and postoperative blood loss with aprotinin (Trasylol) during extracorporeal circulation. Arch Malad Coeur Vaisseaux 1991;84: 1797-802.
26. Vedrinne C, Girard C, Jegaden O, et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth 1992;6:319-23.
27. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992;6:324-7.
28. Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction: a scanning electron microscope study. Circulation 1992;86(Suppl):II405-9.
29. Cosgrove DM, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-6.
30. Baele PL, Ruiz-Gomez J, Londot C, et al. Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acta Anaesthesiol Belg 1992;43: 103-12.
31. Bailey CR, Kelleher AA, Wielogorski AK. Randomised placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery. Br J Surg 1994;81:969-73.
32. Carrera A, Martinez MV, Garcia-Guiral M, et al. Use of high doses of aprotinin in cardiac surgery. Rev Espan Anestesiol Reanim 1994;41:13-9.
33. Maccario M, Fumagalli C, Deangelis R, et al. Comparison between low and high doses of aprotinin in heart surgery. Miner Anestesiol 1994;60:315-20.
34. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107:554-61.
35. Swart MJ, Gordon PC, Hayse-Gregson PB, et al. High-dose aprotinin in cardiac surgery: a prospective, randomized study. Anaesth Intensive Care 1994;22:529-33.
36. Rocha E, Hidalgo F, Llorens R, et al. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994;90:921-7.
37. Casas JI, Zuazu-Jausoro I, Mateo J, et al. Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1995;110:1107-17.
38. Penta de Peppo A, Danilo Pierri M, Scafuri A, et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. TX Heart Inst J 1995;22:231-6.
39. Corbeau JJ, Monrigal JP, Jacob JP, et al. Comparaison des effet de l'aprotinine et de l'acide tranexamique sur le saignement en chirurgie cardiaque. Ann Fr Anesth Reanim 1995;14:154-61.
40. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92:2236-44.
41. Lab M, Welz A, Kochs M, et al. Aprotinin in elective primary bypass surgery: graft patency and clinical efficacy. Eur J Cardiothorac Surg 1995;9:206-10.
42. Dietrich W, Dilthey G, Spannagl M, et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite-and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 1995;83: 679-89.
43. D'Ambra MN, Akins CW, Blackstone E, et al. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 1996;112:1081-9.
44. Harder MP, Eijsman L, Roozendaal KJ, et al. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991;51: 936-41.
45. Isetta C, Gunness TK, Samat C, et al. Antifibrinolytic treatment and homologous transfusion in cardiac surgery. Eur Heart J 1993;14:424.
46. Liu B, Belboul A, Radberg G, et al. Effect of reduced aprotinin dosage on blood loss and use of blood products in patients undergoing cardiopulmonary bypass. Scand J Thorac Cardiovasc Surg 1993;27:149-55.
47. Blauhut B, Harringer W, Bettelheim P, et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994;108:1083-91.
48. Hardy JF, Desroches J, Belisle S, et al. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients. Can J Anaesth 1993;40:625-31.
49. Bailey CR, Wielogorski AK. Randomised placebo-controlled double-blind study of two low-dose aprotinin regimens in cardiac surgery. Br Heart J 1994;71:349-53.
50. Tabuchi N, Huet RC, Sturk A, et al. Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass. Ann Thorac Surg 1994;58:1036-9.
51. Pugh SC, Wielogorski AK. A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1995;9:240-4.
52. Speekenbrink RG, Vonk AB, Wildevuur CR, Eijsman L. Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995;59:438-42.
53. Alvarez JM, Quiney NF, McMillan D, et al. The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. J Cardiothorac Vasc Anesth 1995;9:29-33.
54. Wendel HP, Heller W, Michel J, et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 1995; 109:1164-72.
55. Bidstrup BP, Royston D, McGuinness C, Sapsford RN. Aprotinin in aspirin-pretreated patients. Perfusion 1990;5(Suppl): 77-81.
56. Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg 1996;37:401-7.
57. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial. N Engl J Med 1986; 314:1402-6.
58. Frankville DD, Harper GB, Lake CL, Johns RA. Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass. Anesthesiology 1991;74:988-96.
59. Horrow JC, Van Riper DF, Strong MD, et al. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991;84:2063-70.
60. Marquez J, Koehler S, Strelec SR, et al. Repeated dose administration of desmopressin acetate in uncomplicated cardiac surgery: a prospective, blinded, randomized study. J Cardiothorac Vasc Anesth 1992;6:674-6.
61. Ansell J, Klassen V, Lew R, et al. Does desmopressin acetate prophylaxis reduce blood loss after valvular heart operations? A randomized, double-blind study. J Thorac Cardiovasc Surg 1992;104:117-23.
62. Gratz I, Koehler J, Olsen D, et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 1992;104:1417-22.
63. Dilthey G, Dietrich W, Spannagl M, Richter JA. Influence of desmopressin acetate on homologous blood requirements in cardiac surgical patients pretreated with aspirin. J Cardiothorac Vasc Anesth 1993;7:425-30.
64. Sheridan DP, Card RT, Pinilla JC, et al. Use of desmopressin acetate to reduce blood transfusion requirements during cardiac surgery in patients with acetylsalicylic-acid-induced platelet dysfunction. Can J Surg 1994;37:33-6.
65. Temeck BK, Bachenheimer LC, Katz NM, et al. Desmopressin acetate in cardiac surgery: a double-blind, randomized study. South Med J 1994;87:611-5.
66. Spyt TJ, Weerasena NA, Bain WH, et al. The effects of desmopressin acetate (DDAVP) on haemostasis and blood loss in routine coronary artery bypass surgery: a randomized, double-blind trial. Perfusion 1990;5(Suppl):57-61.
67. Horrow JC, Van Riper DF, Strong MD, et al. The dose-response relationship of tranexamic acid. Anesthesiology 1995;82:383-92.
68. Coffey A, Pittmam J, Halbrook H, et al. The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial. Am Surg 1995;61: 566-8.
69. Katsaros D, Petricevic M, Snow NJ, et al. Tranexamic acid reduces postbypass blood use: a double-blind, prospective, randomized study of 210 patients. Ann Thorac Surg 1996;61:1131-5.
70. Shore-Lesserson L, Reich DL, Vela-Cantos F, et al. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Anesth Analg 1996;83:18-26.
71. Daily PO, Lamphere JA, Dembitsky WP, et al. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: a randomized, prospective, double-blind study. J Thorac Cardiovasc Surg 1994;108:99-106.
72. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-5.
73. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ, for the Retrovirus Epidemiology Donor Study. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-90.
74. Busch ORC, Hop WCJ, Hoyneck van Papendrecht MAW. Blood transfusion and prognosis in colorectal cancer. N Engl J Med 1993;328:1372-6.
75. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994;12:1859-67.
76. Busch ORC, Marquet RL, Hop WCJ, Jeekel J. Colorectal cancer recurrence and perioperative blood transfusions: a critical reappraisal. Semin Surg Oncol 1994;10:195-9.
77. Chung M, Steinmetz OK, Gordon PH. Perioperative boood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993;80:427-32.
78. Vamvakas E, Moore SB. Perioperative blood transfusion and colorectal cancer recurence: a qualitative statistical overview and meta-analysis. Transfusion 1993;33:754-65.
79. Duffy G, Neal KR. Differences in post-operative infection rates between patients receiving autologous and allogeneic blood transfusion: a meta-analysis of published randomized and nonrandomized studies. Transfus Med 1996;6:325-8.
80. Smith PK, Muhlbaier LH. Aprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg 1996;62:1575-7.
81. van der Meer J, Hillege HL, Ascoop CAPL, et al. Aprotinin in aortocoronary bypass surgery: increased risk of vein graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thromb Haemostas 1996;15:1-3.
82. Jegaden O, Vedrinne C, Rossi R. Aprotinin does not compromise arterial graft patency in coronary bypass operations. J Thorac Cardiovasc Surg 1993;106:180-1.
83. Brzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials. Ann Intern Med 1995; 123:873-7.
84. Egger M, Davey Smith G. Misleading meta-analysis: lessons from "an effective, safe, simple" intervention that wasn't. BMJ 1995;310:752-4.
85. Lemmer JH Jr. Reporting the results of blood conservation studies: the need for uniform and comprehensive methods. Ann Thorac Surg 1994;58:1305-6.
86. Sirchia G, Giovanetti G, McClelland B, Fracchia GN. Safe and good use of blood in surgery (SANGUIS): use of blood products and artificial colloids in 43 European hospitals. Luxemburg: European Commission, 1994.